Cargando…

Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation

Many women take drugs during their pregnancy to treat a variety of clinical conditions. To optimize drug efficacy and reduce fetal toxicity, it is important to determine or predict fetal drug exposure throughout pregnancy. Previously, we developed and verified a maternal-fetal physiologically based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anoshchenko, Olena, Storelli, Flavia, Unadkat, Jashvant D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Pharmacology and Experimental Therapeutics 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626637/ https://www.ncbi.nlm.nih.gov/pubmed/34426410 http://dx.doi.org/10.1124/dmd.121.000538

Ejemplares similares

Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome
por: Anoshchenko, Olena, et al.
Publicado: (2021)

Successful Prediction of Human Steady‐State Unbound Brain‐to‐Plasma Concentration Ratio of P‐gp Substrates Using the Proteomics‐Informed Relative Expression Factor Approach
por: Storelli, Flavia, et al.
Publicado: (2021)

Gestational Age–Dependent Abundance of Human Placental Transporters as Determined by Quantitative Targeted Proteomics
por: Anoshchenko, Olena, et al.
Publicado: (2020)

Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model
por: Peng, Jinfu, et al.
Publicado: (2022)

Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes
por: Ladumor, Mayur K., et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation
por: Le Merdy, Maxime, et al.
Publicado: (2022)

Abundance of P-glycoprotein and Breast Cancer Resistance Protein Measured by Targeted Proteomics in Human Epileptogenic Brain Tissue
por: Brukner, Aniv Mann, et al.
Publicado: (2021)

Comparison of Heavy Labeled (SIL) Peptide versus SILAC Protein Internal Standards for LC-MS/MS Quantification of Hepatic Drug Transporters
por: Prasad, Bhagwat, et al.
Publicado: (2014)

Editorial: Exploring Maternal-Fetal Pharmacology Through PBPK Modeling Approaches
por: Dallmann, André, et al.
Publicado: (2022)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery
por: Naga, Doha, et al.
Publicado: (2022)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Building in-house PBPK modelling tools for oral drug administration from literature information
por: Grandoni, Silvia, et al.
Publicado: (2019)

Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole
por: Shah, Harsh, et al.
Publicado: (2023)

SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp(®) simulator
por: Khalidi, Hiba, et al.
Publicado: (2022)

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Proposed PBPK Model to Predict Infant Exposure to Toxic Chemicals in Breast Milk
por: Soldin, OP
Publicado: (2002)

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates
por: Reddy, Micaela B., et al.
Publicado: (2021)

Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
por: Rowland, M
Publicado: (2013)

PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
por: Ferreira, Abigail, et al.
Publicado: (2021)

Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers
por: Wedagedera, Janak R., et al.
Publicado: (2022)

Erratum: Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
Publicado: (2019)

PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure.
por: Thomas, R S, et al.
Publicado: (1996)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Prediction of Drug–Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
por: Ji, Beihong, et al.
Publicado: (2019)

Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure.
por: Clewell, Rebecca A, et al.
Publicado: (2002)

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
por: Darwich, A S, et al.
Publicado: (2013)

Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling
por: Mao, Jialin, et al.
Publicado: (2018)

Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?
por: Ibarra, Manuel, et al.
Publicado: (2020)

Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation
por: Zhao, P
Publicado: (2017)

Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation
por: McNally, Kevin, et al.
Publicado: (2012)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach
por: Cox, Emily J., et al.
Publicado: (2021)

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
por: Wu, Xiaofei, et al.
Publicado: (2022)

A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation
por: Ladumor, Mayur K., et al.
Publicado: (2019)

Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care
por: van der Heijden, Joyce E. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t24oua51kfspb1eq1tnpkk5hc2